Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

NCT06287918 is registered in ClinicalTrials.gov with 3H (Suzhou) Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06287918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06287918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
Lead sponsor
3H (Suzhou) Pharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
June 30, 2028
Enrollment
130 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors with fgfr2 alterations, adult